EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE


facebook twitter youtube
News archive
Recent news

 

ASH 2019, Orlando – Belantamab mafodotin is a new myeloma drug that has shown very promising results. The clinical trial Dreamm-3 was presented yesterday at the American Society of Hematology (ASH) Annaul Congress and it is expected to be the European approval trial for this drug.

Dr Katja Weisel, University Medical Center Hamburg-Eppendorf in Germany, explains for Myeloma Patients Europe (MPE) what we need to know about this first-in-class drug.

 







Recent news

» Watch the webinar on ASH 2020 myeloma and AL amyloidosis highlights

» ASH 2020 AL amyloidosis highlights

Leave a Reply

Your email address will not be published. Required fields are marked *

I accept the Privacy Policy * for Click to select the duration you give consent until.